Compare NPKI & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NPKI | XERS |
|---|---|---|
| Founded | 1932 | 2005 |
| Country | United States | United States |
| Employees | 510 | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.0B |
| IPO Year | N/A | 2021 |
| Metric | NPKI | XERS |
|---|---|---|
| Price | $15.76 | $6.24 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $14.17 | $10.83 |
| AVG Volume (30 Days) | 754.4K | ★ 1.2M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | $16.39 | $34.37 |
| Revenue Next Year | $11.70 | $22.86 |
| P/E Ratio | $38.65 | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $7.63 | $4.30 |
| 52 Week High | $16.50 | $10.08 |
| Indicator | NPKI | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 57.11 | 55.09 |
| Support Level | $13.58 | $5.79 |
| Resistance Level | N/A | $6.41 |
| Average True Range (ATR) | 0.81 | 0.21 |
| MACD | 0.04 | 0.02 |
| Stochastic Oscillator | 69.80 | 62.99 |
NPK International Inc is a temporary worksite access solutions company that manufactures, sells, and rents recyclable composite matting products, along with a full suite of services, including planning, logistics, and site restoration. The company generates majority of revenue from the rental of recyclable composite matting systems, along with related site construction and services to customers in various markets including power transmission, oil and natural gas exploration and production, pipeline, renewable energy, petrochemical, construction and other industries within the United States and United Kingdom. It generates maximum revenue from United States.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.